Dimethylamine

Dimethylamine

SCHEMBL6945823

CCN1CCC(=O)CC1.CNC

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.36
KMT2A Q03164 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
LMNA P02545 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
SETD7 Q8WTS6 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CHRNA7 P36544 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL124152 0.93
Iodide SCHEMBL8818510 0.90 CYP2D6 (0.39) CYP2D6KMT2AHRH3HTR2AHTR2C
Bromide SCHEMBL3729198 0.90 CYP2D6 (0.39) CYP2D6KMT2AHRH3HTR2AHTR2C
Hydrochloric Acid SCHEMBL2171665 0.90 LMNA (0.40) CYP2D6KMT2AHRH3HTR2AHTR2C
Iodomethane SCHEMBL600545 0.88 CYP2D6 (0.38) CYP2D6KMT2AHRH3HTR2AHTR2C
Diethylamine SCHEMBL6948448 0.86 TP53 (0.35) CYP2D6KMT2AHRH3HTR2AHTR2C
Diethylamine SCHEMBL8099606 0.86 TP53 (0.35) CYP2D6KMT2AHRH3HTR2AHTR2C
SCHEMBL6613931 0.84 CYP2D6 (0.44) CYP2D6KMT2AHRH3CYP3A4TSHR
SCHEMBL8115348 0.83 KDM4E (0.37) CYP2D6KMT2ACYP3A4TSHRHSD17B10
SCHEMBL6949948 0.83 KDM4E (0.37) CYP2D6KMT2ACYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 CYP2D6 1607/4885KMT2A 728/4885HRH3 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.